论文部分内容阅读
目的:研究伊伐布雷定联合比索洛尔对冠心病经皮冠状动脉介入(PCI)术后患者心脏康复的影响。方法:选取于某院行PCI术的冠心病患者84例,随机分为观察组(n=42)及对照组(n=42),观察组在常规冠心病二级预防治疗的基础上给予比索洛尔1.25 mg联合伊伐布雷定治疗,对照组在常规冠心病二级预防治疗的基础上仅给予比索洛尔5~10 mg口服。分别于治疗前、治疗4周及治疗12周时监测两组患者的6 min步行实验的距离、6 min步行实验的心率及血氧饱和度、左室射血分数、左室收缩末期内径、左室舒张末期内径、左室间隔厚度及左心室壁厚度。结果:观察组与对照组比较,在治疗12周时,6min步行试验的距离、LVEF及左室正常舒张功能的比例明显增加,LVEDD、LVESD及6 min步行实验时的心室率明显降低,差异均具有统计学意义(P<0.05);与治疗前相比,在治疗4周及12周时,观察组的6 min步行试验的距离、LVEF及左室正常舒张功能的比例明显增加,LVEDD、LVESD及6 min步行实验时的心室率明显降低,差异均具有统计学意义(P<0.05);研究期间,观察组不良反应发生率低于对照组,但无统计学差异(P>0.05)。结论:伊伐布雷定联合比索洛尔对冠心病PCI术后患者的心脏康复的长期效果优于单纯比索洛尔治疗,不增加不良反应,是一种安全有效的治疗方案。
Objective: To investigate the effect of ivabradine combined with bisoprolol on cardiac rehabilitation in patients with coronary artery disease after percutaneous coronary intervention (PCI). Methods: Eighty-four patients with coronary heart disease undergoing PCI in a hospital were randomly divided into observation group (n = 42) and control group (n = 42). The observation group was given peso on the basis of secondary prevention and treatment of conventional coronary heart disease Lorol 1.25 mg combined with ivabradine treatment, the control group in the conventional secondary prevention and treatment of coronary heart disease on the basis of only given bisoprolol 5 ~ 10 mg orally. The distance of 6-minute walking test, heart rate and oxygen saturation, left ventricular ejection fraction, left ventricular end systolic diameter, left ventricular end-diastolic diameter End-diastolic diameter, left ventricular septal thickness, and left ventricular wall thickness. Results: Compared with the control group, the ratio of LVEF and left ventricular diastolic function in the 6-minute walk test significantly increased at 12 weeks of treatment. The LVEDD, LVESD and ventricular rate at 6-minute walk were significantly decreased (P <0.05). Compared with those before treatment, the ratio of LVEF and left ventricular normal diastolic function in the 6-min walk test in the observation group was significantly increased at 4 weeks and 12 weeks after treatment. LVEDD, LVESD (P <0.05). During the study period, the incidence of adverse reactions in the observation group was lower than that in the control group, but there was no significant difference (P> 0.05). Conclusion: The long-term effect of the combination of ivabradine and bisoprolol on cardiac rehabilitation in patients with coronary artery disease after PCI is better than that of simple bisoprolol treatment without any adverse reactions. Therefore, it is a safe and effective treatment regimen.